T1	intervention 41 50	tamoxifen
T2	No-of-participants 394 398	1884
T3	eligibility 399 435	recently postmenopausal women on HRT
T4	control 497 504	placebo
T5	duration 509 516	5 years
T6	outcome-Measure 544 567	breast cancer incidence
T7	outcome 621 635	breast cancers
T8	control-value 618 620	24
T9	intervention-value 651 653	19
T10	outcome 736 762	trends in luminal-A tumors
T11	outcome 1024 1047	coronary heart syndrome
T12	control-value 1049 1050	6
T13	intervention-value 1058 1059	4
T14	outcome 1062 1084	cerebrovascular events
T15	control-value 1086 1087	2
T16	intervention-value 1095 1096	5
T17	outcome 1099 1102	VTE
T18	control-value 1104 1105	2
T19	intervention-value 1113 1114	5
T20	outcome 1120 1135	uterine cancers
T21	control-value 1137 1138	3
T22	intervention-value 1146 1147	1
T23	outcome 1150 1168	Vasomotor symptoms
T24	intervention-value 1174 1177	50%
